|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Aberrant fucosylation enables breast cancer clusterin to interact with dendritic cell-specific ICAM-grabbing non-integrin (DC-SIGN).
|
31428526 |
2019 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Extracellular Hsp90α and clusterin synergistically promote breast cancer epithelial-to-mesenchymal transition and metastasis via LRP1.
|
31273033 |
2019 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The objective of this explorative study was to determine whether clusterin expression in breast cancer correlated with clinical pathologic characteristics and whether its expression was predictive of response to neoadjuvant chemotherapy (NAC).
|
28890185 |
2018 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe the use of clusterin-specific antisense oligonucleotides and siRNA to sensitize breast carcinoma cells to several PKIs.
|
25144344 |
2015 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression.
|
23174100 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer.
|
22369881 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
CLU may regulate the aggressive behaviour of human breast cancer cells through modulation of ERK signalling and MMP9 expression.
|
22613415 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our study suggests a role of genetic variation in BIRC5, BCL2 and CLU as progression and prognostic markers for BC, supporting previous studies based on the expression of the genes.
|
22037783 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has been reported that the elevated level of secreted clusterin (sClu) protein is associated with poor survival in breast cancer patients and can induce metastasis in rodent models.
|
23099883 |
2012 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review focuses on recent discoveries concerning the role of CLU in prostate and breast cancer onset and progression.
|
19903745 |
2010 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To investigate the role of secretory clusterin in the biology of breast cancer tumor growth and resistance to therapy we have engineered an MCF-7 cell line (MCF-7CLU) that over-expresses clusterin.
|
20307318 |
2010 |
|
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
This concept was corroborated by in vitro studies showing that silencing of CLU restored toremifene sensitivity in the ER anti-estrogen-resistant breast cancer cell line T47D.
|
18508997 |
2008 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer.
|
17689225 |
2007 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, glucocorticoid activation in breast cancer cells regulates survival signaling by the direct transactivation of genes like clusterin which encode proteins that decrease susceptibility to apoptosis.
|
18078515 |
2007 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In human breast cancer MCF-7 cells, 2k10-siRNA-sCLU nanocomplexes suppressed both basal as well as IR-induced sCLU protein expression, which led to an over 3-fold increase in IR-induced lethality over 2k10-siRNA scrambled controls.
|
17722531 |
2006 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The objectives of this study were to evaluate clusterin expression levels in human breast cancer and to determine whether antisense oligonucleotides or double-stranded small interfering RNAs (siRNA) targeting the clusterin gene enhance apoptosis induced by paclitaxel.
|
16373699 |
2005 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether our findings suggest that combined targeting of HER-2 and CLU may represent a novel, rational approach to breast cancer therapy.
|
15685647 |
2005 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The purpose of this study was to examine clusterin expression in a large series of breast carcinomas by immunohistochemistry and in situ hybridization.
|
10934144 |
2000 |
|
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Relationship between variant forms of estrogen receptor RNA and an apoptosis-related RNA, TRPM-2, with survival in patients with breast cancer.
|
8252481 |
1993 |